About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
The authors describe a study in which “bipolar families,” compared with families without a serious mental illness, incurred much higher medical costs, visited physicians more often, had more hospital stays, and spent more money on prescription drugs.
Mary Lou Chatterton, PharmD, Xiongkan Ke, MS, Barbara Edelman Lewis, PhD, MHA, Krithika Rajagopalan, PhD, and Arthur Lazarus, MD, MBA
Second-generation atypical antipsychotic drugs carry a lower risk of extrapyramidal symptoms and tardive dyskinesia compared with conventional agents, but they are not without their dangers. The case report of a 46-year-old patient demonstrates the point that the newer agents should be used according to their FDA-approved indications, when possible, and that patients using aripiprazole, an “atypical atypical” agent, need to be carefully monitored.
Thomas Schwartz, MD, and Shafi Raza, MD
Although the “vaccine revolution” has resulted in products that can prevent illness and reduce costs of disease, the authors raise several concerns: who will pay for these improvements, how these advances will alter treatment, how cost and efficacy will be balanced, and how to choose the right product.
Jonathan A. McCullers, MD, and Jeffrey D. Dunn, PharmD, MBA
Presentations cover a number of clinical trials of cardiac agents, including clopidogrel versus prasugrel; an investigative thrombin receptor antagonist; a niacin/simvastatin combination; warfarin dosing versus genotype-guided dosing; clopidogrel eptifibatide, and bivalirudin; and eptifibatide versus abciximab.
Topics include nilotinib (Tasigna Capsules) for the treatment of chronic myelogenous leukemia (CML), raltegravir (Isentress) for patients with HIV-1 infection, and ixabepilone (Ixempra), combined with capecitabine (Xeloda), for use in metastatic or locally advanced breast cancer.
Marvin M. Goldenberg, PhD, RPh, MS
David Nash, MD, MBA, reviews Better: A Surgeon’s Notes on Performance, a book in which Dr. Atul Gawande asserts that our health care system won’t improve until we rethink our everyday practices.
David Nash, MD, MBA
In Part 2 of a two-part series, Matthew Grissinger, RPh, FASCP, details the steps needed for safely prescribing and dispensing patient-controlled analgesia (PCA).
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses how consumers might have access to a number of “behind-the-counter” drugs only after they are counseled by a pharmacist.
From cephipeme to valsartan, P&T presents the latest information about FDA approvals, new indications, recalls, and industry updates.
Drs. Colabella and Chagan review dalbavancin (Zeven), a glycopeptide for resistant gram-positive organisms.
Jennifer Colabella, PharmD, and Larisa Chagan, PharmD, BCPS